The use of efferent therapy techniques in the complex treatment of patients suffering from chronic Epstein – Barr virus infection

Abstract

The possibility of using efferent therapy techniques in the complex treatment of patients with chronic Epstein – Barr virus infection is substantiated. It was established that prior to the therapy, the fluctuation in the number of copies of the deoxyribonucleic acid of Epstein – Barr virus per 1 ml of saliva sample in the group of patients suffering from chronic Epstein – Barr virus ranged from 1×103 to 9,68×105 copies. 10 days after the course of procedures (plasma exchange+plasma sorption), 55% of patients showed a significantly significant decrease in the number of copies of the deoxyribonucleic acid of Epstein – Barr virus from 327483,33±87070,83 to 13323±3789,96 (p=0,001) and 44,83% of patients received negative results of the polymerase chain reaction. Half of patients with initially high content of deoxyribonucleic acid copies (105–104 copies) had a negative polymerase chain reaction in saliva samples, half of another patients showed a significantly significant decrease in the number of deoxyribonucleic acid copies. In patients with a low number of copies, the opposite effect is observed, that is, after a course of efferent therapy, the number of copies of Epstein – Barr deoxyribonucleic acid tends to increase, as confirmed by the polymerase chain reaction in saliva samples. This is due to the release of free virus particles from the depot areas due to the diffusion of an increased volume of circulating blood during the procedures. However, in the general group of patients, the level of antibodies of the immunoglobulin G class to the nuclear antigen of the Epstein – Barr virus in the blood serum tends to decrease, and the level of antibodies of the immunoglobulin G class to the capsid protein of the Epstein – Barr virus significantly decreases after efferent therapy. After a course of plasma exchange+plasma adsorption, patients have no complaints of pain in the throat and joints, low-grade fever, chills, sweating and manifestations of stomatitis. The course application of plasma exchange+plasma adsorption increases the effectiveness of standard antiviral therapy and can be recommended for patients suffering from chronic Epstein-Barr virus infection as part of a comprehensive treatment.

Keywords

chronic Epstein – Barr virus infection / congenital immune response / efferent therapy / plasma exchange / plasma sorption / number of copies of deoxyribonucleic acid / antibodies to the capsid antigen Epstein – Barr virus / antibodies to the nuclear antigen of Epstein – Barr virus

References

[1] Abe, H. Removal of parvovirus B19 from hemoglobin solution by nanofiltration / H. Abe [et al.] // Artif. Cells Blood Substit. Immobil. Biotechnol. – 2000. – № 5. – P. 375–383.

[2] Bernasconi, M.C. Quantitative profiling of housekeeping and Epstein-Barr virus gene transcription in Burkitt lymphoma cell lines using an oligonucleotide microarray / M.C. Bernasconi [et al.] // Virol. – 2006. – Vol. 3. – Р. 43.

[3] Brandwein, H. Membrane filtration for virus removal / H. Brandwein, H. Aranha-Creado // Dev. Biol. – 2000. – Vol. 102. – Р.157–163.

[4] Burnouf, T. Reducing the risk of infection from plasma products; specific preventative strategies / T. Burnouf, M. Radosevich // Blood Rev. – 2000. – Vol. 14. – Р. 94–110.

[5] Burnouf, T. Nanofiltration of plasma-derived biopharmaceutical products / T. Burnouf, M. Radosevich // Haemophilia. – 2003. – № 1. – Р. 24–37.

[6] Graf, E.G. Virus removal by filtration / E.G. Graf [et al.] //Dev. Biol. Stand. – 1999. – Р. 9989–9994.

[7] Hurley, E.A. When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates / E.A. Hurley [et al.] // J. Virol. – 1991. – Vol. 65. – Р. 1245–1254.

[8] Kaschka-Dierich, C.L. Human lymphoblastoid cell lines derived from individuals without lymphoproliferative disease contain the same latent forms of Epstein-Barr virus DNA as those found in tumor cells / C.L. Kaschka-Dierich [et al.] // Int. J. Cancer. – 1977. – Vol. 20. – Р.173–180.

[9] Koliais, S.I. Mode of integration of Epstein-Barr virus genome into host DNA in Burkitt lymphoma cells / S.I. Koliais // J. Gen. Virol. – 1979. – Vol. 44. – Р. 573–576.

[10] Kripalani-Joshi, S. Identification of integrated Epstein-Barr virus in nasopharyngeal carcinoma using pulse field gel electrophoresis / S. Kripalani-Joshi, H.Y. Law // Int. J. Cancer. – 1994. – Vol. 56. – Р. 187–192.

[11] Luo, W.-J. Epstein–Barr virus is integrated between REL and BCL-11A in American Burkitt lymphoma cell line (NAB-2) / W.-J. Luo [et al.] // Laboratory Investigation. – 2004. – Vol. 84. – Р. 1193–1199.

[12] Matsuo, T.M. Persistence of the entire Epstein-Barr virus genome integrated into human lymphocyte DNA / T.M. Matsuo [et al.] // Science. –1984. – Vol. 226. – Р. 1322–1325.

[13] O’Grady, J. Virus removal studies using nanofiltration membranes / J. O’Grady [et al.] // Dev. Biol. Stand. – 1996. – Vol. 88. – Р. 319–326.

[14] Oshima, K.H. Integrated Epstein-Barr virus (EBV) and chromosomal abnormality in chronic active EBV infection / K.H. Oshima [et al.] // Int. J. Cancer. – 1997. – Vol. 71. – Р. 943–947.

[15] Oshima, K.H. Comparison of filtration properties of hepatitis B virus, hepatitis C virus and simian virus 40 using a poly- vinylidene fluoride membrane filter / K.H. Oshima [et al.] // Vox Sang. – 1998. – Vol. 75. – Р. 181–188.

[16] Prowse, C. Human parvovirus B19 and blood products / C. Prowse [et al.] // Vox Sang. – 1997. – Vol. 72. – Р. 1–10.

[17] Validation Guide VG-DV20, Pall ULTIPOR VF Grade DV20 AB style virus removal filter cartridges // Pall Bio Pharmaceuticals. – 2002. – Р. 1–28.

[18] Yokoyama, T. Removal of small non-enveloped viruses by nanofiltration / T. Yokoyama [et al.] // Vox. Sang. – 2004. – Vol. 86, № 4. – Р. 225–229.

RIGHTS & PERMISSIONS

Rakityanskaya I.A., Ryabova T.S., Todzhibaev U.A., Kalashnikov A.A., Belskich A.N., Zakharov M.V., Manuilov A.S., Savateev A.V.